vTv Therapeutics Inc. (NASDAQ:VTVT) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a report released on Wednesday, July 5th.
According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
Several other equities analysts have also weighed in on VTVT. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of vTv Therapeutics in a report on Thursday, March 30th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $24.00 price target on shares of vTv Therapeutics in a report on Thursday, March 30th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. vTv Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $14.30.
Shares of vTv Therapeutics (NASDAQ:VTVT) opened at 4.42 on Wednesday. The firm has a 50-day moving average of $4.82 and a 200 day moving average of $5.39. vTv Therapeutics has a 12 month low of $4.42 and a 12 month high of $7.50. The company’s market capitalization is $42.84 million.
vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.20 million. On average, equities research analysts expect that vTv Therapeutics will post ($1.16) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “vTv Therapeutics Inc. (VTVT) Cut to Sell at Zacks Investment Research” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/07/25/zacks-investment-research-downgrades-vtv-therapeutics-inc-vtvt-to-sell-updated-updated.html.
A number of hedge funds have recently bought and sold shares of VTVT. Renaissance Technologies LLC boosted its stake in vTv Therapeutics by 4.8% in the first quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 2,900 shares during the last quarter. Sphera Funds Management LTD. raised its position in shares of vTv Therapeutics by 50.0% in the first quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biotechnology company’s stock worth $1,965,000 after buying an additional 100,000 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of vTv Therapeutics by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,305 shares during the last quarter. Essex Investment Management Co. LLC purchased a new position in shares of vTv Therapeutics during the first quarter worth $261,000. Finally, Candriam Luxembourg S.C.A. bought a new stake in shares of vTv Therapeutics during the first quarter worth $917,000. 11.12% of the stock is currently owned by institutional investors and hedge funds.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.